Journal Article
. 2011 May;104(11).
doi: 10.1038/bjc.2011.145.

Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial

P-L Jerevall 1 X-J Ma  H Li  R Salunga  N C Kesty  M G Erlander  D C Sgroi  B Holmlund  L Skoog  T Fornander  B Nordenskjöld  O Stål  
Affiliations
  • PMID: 21559019
  •     20 References
  •     63 citations

Abstract

Background: A dichotomous index combining two gene expression assays, HOXB13:IL17BR (H:I) and molecular grade index (MGI), was developed to assess risk of recurrence in breast cancer patients. The study objective was to demonstrate the prognostic utility of the combined index in early-stage breast cancer.

Methods: In a blinded retrospective analysis of 588 ER-positive tamoxifen-treated and untreated breast cancer patients from the randomised prospective Stockholm trial, H:I and MGI were measured using real-time RT-PCR. Association with patient outcome was evaluated by Kaplan-Meier analysis and Cox proportional hazard regression. A continuous risk index was developed using Cox modelling.

Results: The dichotomous H:I+MGI was significantly associated with distant recurrence and breast cancer death. The >50% of tamoxifen-treated patients categorised as low-risk had <3% 10-year distant recurrence risk. A continuous risk model (Breast Cancer Index (BCI)) was developed with the tamoxifen-treated group and the prognostic performance tested in the untreated group was 53% of patients categorised as low risk with an 8.3% 10-year distant recurrence risk.

Conclusion: Retrospective analysis of this randomised, prospective trial cohort validated the prognostic utility of H:I+MGI and was used to develop and test a continuous risk model that enables prediction of distant recurrence risk at the patient level.

Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer.
P M Ravdin, L A Siminoff, +4 authors, H L Parker.
J Clin Oncol, 2001 Feb 22; 19(4). PMID: 11181660
Highly Cited.
Predictive relevance of HOXB13 protein expression for tamoxifen benefit in breast cancer.
Piiha-Lotta Jerevall, Agneta Jansson, +3 authors, Olle Stål.
Breast Cancer Res, 2010 Jul 24; 12(4). PMID: 20649975    Free PMC article.
A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen.
Xiao-Jun Ma, Zuncai Wang, +27 authors, Dennis C Sgroi.
Cancer Cell, 2004 Jun 15; 5(6). PMID: 15193263
Highly Cited.
Cytosol estradiol receptor in human mammary carcinoma: an assay based on isoelectric focusing in polyacrylamide gel.
O Wrange, B Nordenskjöld, J A Gustafsson.
Anal Biochem, 1978 Apr 01; 85(2). PMID: 565601
Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases.
C L Carter, C Allen, D E Henson.
Cancer, 1989 Jan 01; 63(1). PMID: 2910416
Highly Cited.
The Nottingham Prognostic Index in primary breast cancer.
M H Galea, R W Blamey, C E Elston, I O Ellis.
Breast Cancer Res Treat, 1992 Jan 01; 22(3). PMID: 1391987
Highly Cited.
HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.
M F Press, L Bernstein, +12 authors, K J Flom.
J Clin Oncol, 1997 Aug 01; 15(8). PMID: 9256133
Highly Cited.
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen.
Matthew P Goetz, Vera J Suman, +9 authors, Fergus J Couch.
Clin Cancer Res, 2006 Apr 13; 12(7 Pt 1). PMID: 16609019
Concordance among gene-expression-based predictors for breast cancer.
Cheng Fan, Daniel S Oh, +5 authors, Charles M Perou.
N Engl J Med, 2006 Aug 11; 355(6). PMID: 16899776
Highly Cited.
The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer.
Xiao-Jun Ma, Susan G Hilsenbeck, +6 authors, Mark G Erlander.
J Clin Oncol, 2006 Sep 30; 24(28). PMID: 17008703
Proliferation: the most prominent predictor of clinical outcome in breast cancer.
Christine Desmedt, Christos Sotiriou.
Cell Cycle, 2006 Sep 14; 5(19). PMID: 16969100
Review.
First--select the target: better choice of adjuvant treatments for breast cancer patients.
A Goldhirsch, A S Coates, +4 authors, St Gallen Expert Panel Members.
Ann Oncol, 2006 Oct 31; 17(12). PMID: 17071934
Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer.
Lars E Rutqvist, Hemming Johansson, Stockholm Breast Cancer Study Group.
Acta Oncol, 2007 Apr 25; 46(2). PMID: 17453361
Exploring the two-gene ratio in breast cancer--independent roles for HOXB13 and IL17BR in prediction of clinical outcome.
Piiha-Lotta Jerevall, Sara Brommesson, +7 authors, Olle Stål.
Breast Cancer Res Treat, 2007 Apr 25; 107(2). PMID: 17453342
Enabling personalized cancer medicine through analysis of gene-expression patterns.
Laura J van't Veer, René Bernards.
Nature, 2008 Apr 04; 452(7187). PMID: 18385730
Highly Cited. Review.
A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer.
Xiao-Jun Ma, Ranelle Salunga, +8 authors, Dennis Sgroi.
Clin Cancer Res, 2008 May 03; 14(9). PMID: 18451222
Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features.
Lori J Goldstein, Robert Gray, +12 authors, Joseph A Sparano.
J Clin Oncol, 2008 Aug 06; 26(25). PMID: 18678838    Free PMC article.
Highly Cited.
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009.
A Goldhirsch, J N Ingle, +4 authors, Panel members.
Ann Oncol, 2009 Jun 19; 20(8). PMID: 19535820    Free PMC article.
Highly Cited.
A gene-expression signature as a predictor of survival in breast cancer.
Marc J van de Vijver, Yudong D He, +18 authors, René Bernards.
N Engl J Med, 2002 Dec 20; 347(25). PMID: 12490681
Highly Cited.
Prognostic utility of the breast cancer index and comparison to Adjuvant! Online in a clinical case series of early breast cancer.
Rachel C Jankowitz, Kristine Cooper, +5 authors, Adam Brufsky.
Breast Cancer Res, 2011 Oct 18; 13(5). PMID: 21999244    Free PMC article.
Practical implications of gene-expression-based assays for breast oncologists.
Aleix Prat, Matthew J Ellis, Charles M Perou.
Nat Rev Clin Oncol, 2011 Dec 07; 9(1). PMID: 22143140    Free PMC article.
Highly Cited. Review.
Hormonal therapy in breast cancer: a model disease for the personalization of cancer care.
Shannon Puhalla, Saveri Bhattacharya, Nancy E Davidson.
Mol Oncol, 2012 Mar 13; 6(2). PMID: 22406404    Free PMC article.
Review.
Centromere protein-A, an essential centromere protein, is a prognostic marker for relapse in estrogen receptor-positive breast cancer.
Susan L McGovern, Yuan Qi, +2 authors, Thomas A Buchholz.
Breast Cancer Res, 2012 May 09; 14(3). PMID: 22559056    Free PMC article.
Gene signatures in breast cancer: current and future uses.
Enrique Espinosa Arranz, Juan Ángel Fresno Vara, Angelo Gámez-Pozo, Pilar Zamora.
Transl Oncol, 2013 Jan 17; 5(6). PMID: 23323153    Free PMC article.
Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement.
H A Azim, S Michiels, +9 authors, C Swanton.
Ann Oncol, 2013 Jan 23; 24(3). PMID: 23337633    Free PMC article.
HOXB13:IL17BR and molecular grade index and risk of breast cancer death among patients with lymph node-negative invasive disease.
Laurel A Habel, Lori C Sakoda, +6 authors, Charles P Quesenberry.
Breast Cancer Res, 2013 Mar 19; 15(2). PMID: 23497539    Free PMC article.
HOXB13 mediates tamoxifen resistance and invasiveness in human breast cancer by suppressing ERα and inducing IL-6 expression.
Nilay Shah, Kideok Jin, +12 authors, Saraswati Sukumar.
Cancer Res, 2013 Jul 09; 73(17). PMID: 23832664    Free PMC article.
Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population.
Dennis C Sgroi, Ivana Sestak, +9 authors, Mitch Dowsett.
Lancet Oncol, 2013 Sep 17; 14(11). PMID: 24035531    Free PMC article.
Highly Cited.
The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials.
Elin Karlsson, Gizeh Pérez-Tenorio, +7 authors, Olle Stål.
Breast Cancer Res, 2013 Oct 18; 15(5). PMID: 24131622    Free PMC article.
An unmet need: tailoring extended adjuvant endocrine therapy.
G Bianchini, L Gianni.
Br J Cancer, 2013 Nov 21; 109(12). PMID: 24253504    Free PMC article.
Nek2 and Plk4: prognostic markers, drivers of breast tumorigenesis and drug resistance.
Mihaela Marina, Harold I Saavedra.
Front Biosci (Landmark Ed), 2014 Jan 07; 19. PMID: 24389189    Free PMC article.
Review.
Breast Cancer Biomarkers: Utility in Clinical Practice.
Fanny Le Du, Naoto T Ueno, Ana M Gonzalez-Angulo.
Curr Breast Cancer Rep, 2014 Jan 15; 5(4). PMID: 24416469    Free PMC article.
Genomic profiling in luminal breast cancer.
Oleg Gluz, Daniel Hofmann, +3 authors, Nadia Harbeck.
Breast Care (Basel), 2014 Feb 20; 8(6). PMID: 24550749    Free PMC article.
Review.
Gene expression analysis in RA: towards personalized medicine.
A N Burska, K Roget, +8 authors, F Ponchel.
Pharmacogenomics J, 2014 Mar 05; 14(2). PMID: 24589910    Free PMC article.
Review.
Biological subtypes of breast cancer: Prognostic and therapeutic implications.
Ozlem Yersal, Sabri Barutca.
World J Clin Oncol, 2014 Aug 13; 5(3). PMID: 25114856    Free PMC article.
Highly Cited. Review.
Genome-based risk prediction for early stage breast cancer.
Christina Adaniel, Komal Jhaveri, Adriana Heguy, Francisco J Esteva.
Oncologist, 2014 Sep 05; 19(10). PMID: 25187476    Free PMC article.
Review.
PROGgeneV2: enhancements on the existing database.
Chirayu Pankaj Goswami, Harikrishna Nakshatri.
BMC Cancer, 2014 Dec 19; 14. PMID: 25518851    Free PMC article.
Highly Cited.
Nomogram for predicting breast conservation after neoadjuvant chemotherapy.
Min Kyoon Kim, Wonshik Han, +12 authors, Dong-Young Noh.
Cancer Res Treat, 2014 Dec 30; 47(2). PMID: 25544577    Free PMC article.
Markers for the identification of late breast cancer recurrence.
Ivana Sestak, Jack Cuzick.
Breast Cancer Res, 2015 Apr 08; 17. PMID: 25848913    Free PMC article.
Review.
Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study.
Dennis C Sgroi, Judy-Anne W Chapman, +10 authors, Michael Pollak.
Breast Cancer Res, 2016 Jan 06; 18(1). PMID: 26728744    Free PMC article.
Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-α-negative breast cancer.
Erik Hilborn, Jelena Gacic, +3 authors, Agneta Jansson.
Br J Cancer, 2016 Jan 08; 114(3). PMID: 26742006    Free PMC article.
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
Lyndsay N Harris, Nofisat Ismaila, +11 authors, American Society of Clinical Oncology.
J Clin Oncol, 2016 Feb 10; 34(10). PMID: 26858339    Free PMC article.
Highly Cited. Review.
Identification and prioritization of candidate genes for symptom variability in breast cancer survivors based on disease characteristics at the cellular level.
Theresa A Koleck, Yvette P Conley.
Breast Cancer (Dove Med Press), 2016 Mar 30; 8. PMID: 27022301    Free PMC article.
Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy.
Richard Buus, Ivana Sestak, +7 authors, Mitch Dowsett.
J Natl Cancer Inst, 2016 Jul 13; 108(11). PMID: 27400969    Free PMC article.
Highly Cited.
Multiparametric Genomic Assays for Breast Cancer: Time for the Next Generation?
Adam M Brufsky, Nancy E Davidson.
Clin Cancer Res, 2016 Aug 16; 22(20). PMID: 27521446    Free PMC article.
From High-Throughput Microarray-Based Screening to Clinical Application: The Development of a Second Generation Multigene Test for Breast Cancer Prognosis.
Jan C Brase, Ralf Kronenwett, +2 authors, Marcus Schmidt.
Microarrays (Basel), 2013 Jan 01; 2(3). PMID: 27605191    Free PMC article.
Review.
Hormonal Modulation of Breast Cancer Gene Expression: Implications for Intrinsic Subtyping in Premenopausal Women.
Sarah M Bernhardt, Pallave Dasari, +3 authors, Wendy V Ingman.
Front Oncol, 2016 Nov 30; 6. PMID: 27896218    Free PMC article.
Review.
Selecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical assessment of commercially available gene expression assays.
David M Hyams, Eric Schuur, +7 authors, Aníbal Nuñez De Pierro.
J Surg Oncol, 2017 Feb 18; 115(6). PMID: 28211064    Free PMC article.
Review.
An exploratory study of host polymorphisms in genes that clinically characterize breast cancer tumors and pretreatment cognitive performance in breast cancer survivors.
Theresa A Koleck, Catherine M Bender, +7 authors, Yvette P Conley.
Breast Cancer (Dove Med Press), 2017 Apr 21; 9. PMID: 28424560    Free PMC article.
Clinical utility of gene-expression signatures in early stage breast cancer.
Maryann Kwa, Andreas Makris, Francisco J Esteva.
Nat Rev Clin Oncol, 2017 Jun 01; 14(10). PMID: 28561071
Highly Cited. Review.
Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades.
Laura J Esserman, Christina Yau, +9 authors, Linda S Lindström.
JAMA Oncol, 2017 Jul 01; 3(11). PMID: 28662222    Free PMC article.
Tamoxifen therapy benefit for patients with 70-gene signature high and low risk.
Laura J van 't Veer, Christina Yau, +6 authors, Linda Sofie Lindström.
Breast Cancer Res Treat, 2017 Aug 05; 166(2). PMID: 28776283    Free PMC article.
Extended Adjuvant Endocrine Therapy in Hormone Receptor-Positive Early Breast Cancer.
Dara B Bracken-Clarke, Mairi W Lucas, Michaela J Higgins.
Breast Care (Basel), 2017 Aug 09; 12(3). PMID: 28785180    Free PMC article.
Review.
Identifying Biomarkers to Select Patients with Early Breast Cancer Suitable for Extended Adjuvant Endocrine Therapy.
Ivana Sestak.
Breast Care (Basel), 2017 Aug 09; 12(3). PMID: 28785181    Free PMC article.
Review.
Use of 21-gene recurrence score assay to individualize adjuvant chemotherapy recommendations in ER+/HER2- node positive breast cancer-A National Cancer Database study.
Prema P Peethambaram, Tanya L Hoskin, +3 authors, Judy C Boughey.
NPJ Breast Cancer, 2017 Oct 27; 3. PMID: 29067357    Free PMC article.
Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer.
Linda S Lindström, Christina Yau, +19 authors, STO Trialists Group.
J Natl Cancer Inst, 2018 Jan 24; 110(7). PMID: 29361175    Free PMC article.
Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Ivana Sestak, Richard Buus, +9 authors, Mitch Dowsett.
JAMA Oncol, 2018 Feb 17; 4(4). PMID: 29450494    Free PMC article.
Highly Cited.
Prognostic & predictive factors for planning adjuvant chemotherapy of early-stage breast cancer.
Onur Esbah, Berna Oksuzoglu.
Indian J Med Res, 2018 Mar 08; 146(5). PMID: 29512598    Free PMC article.
Review.
Practical consensus recommendations on management of HR + ve early breast cancer with specific reference to genomic profiling.
S Aggarwal, A Vaid, +10 authors, D Doval.
South Asian J Cancer, 2018 May 04; 7(2). PMID: 29721472    Free PMC article.
Clinical application and utility of genomic assays in early-stage breast cancer: key lessons learned to date.
S K L Chia.
Curr Oncol, 2018 Jun 19; 25(Suppl 1). PMID: 29910655    Free PMC article.
Review.
Gene expression assay and Watson for Oncology for optimization of treatment in ER-positive, HER2-negative breast cancer.
Yun Yeong Kim, Se Jeong Oh, +2 authors, Heung Kyu Park.
PLoS One, 2018 Jul 07; 13(7). PMID: 29979736    Free PMC article.
Genomic Testing in the Management of Early-Stage Breast Cancer.
Sima Ehsani, Kari Braun Wisinski.
J Clin Outcomes Manag, 2017 May 01; 24(5). PMID: 30158821    Free PMC article.
An Update on Breast Cancer Multigene Prognostic Tests-Emergent Clinical Biomarkers.
André Filipe Vieira, Fernando Schmitt.
Front Med (Lausanne), 2018 Sep 21; 5. PMID: 30234119    Free PMC article.
Review.
Panoptic View of Prognostic Models for Personalized Breast Cancer Management.
Geetanjali Saini, Karuna Mittal, +3 authors, Ritu Aneja.
Cancers (Basel), 2019 Sep 11; 11(9). PMID: 31500225    Free PMC article.
Review.
Multigene expression signatures in early hormone receptor positive HER 2 negative breast cancer.
Tanja Ovcaricek, Iztok Takac, Erika Matos.
Radiol Oncol, 2019 Sep 26; 53(3). PMID: 31553709    Free PMC article.
Review.
Menstrual cycle associated changes in hormone-related gene expression in oestrogen receptor positive breast cancer.
Ben P Haynes, Ophira Ginsburg, +19 authors, Mitch Dowsett.
NPJ Breast Cancer, 2019 Nov 23; 5. PMID: 31754627    Free PMC article.
Prognosis and endocrine therapy selection for patients with low hormone receptor-positive breast cancer following neoadjuvant chemotherapy: A retrospective study of 570 patients in China.
Yuqin Ding, Kaijing Ding, +6 authors, Xiaowen Ding.
Oncol Lett, 2019 Dec 07; 18(6). PMID: 31807179    Free PMC article.
Indications for prognostic gene expression profiling in early breast cancer.
Erin F Cobain, Daniel F Hayes.
Curr Treat Options Oncol, 2015 May 02; 16(5). PMID: 25929335
Review.
A census of pathway maps in cancer systems biology.
Brent M Kuenzi, Trey Ideker.
Nat Rev Cancer, 2020 Feb 19; 20(4). PMID: 32066900    Free PMC article.
Review.
Cancer genomics predicts disease relapse and therapeutic response to neoadjuvant chemotherapy of hormone sensitive breast cancers.
Jieqiang Zhu, Levan Muskhelishvili, +2 authors, Minjun Chen.
Sci Rep, 2020 May 20; 10(1). PMID: 32424219    Free PMC article.
Multi-Gene Prognostic Signatures and Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in ER-positive, HER2-negative Breast Cancer Patients.
Claudia Mazo, Stephen Barron, Catherine Mooney, William M Gallagher.
Cancers (Basel), 2020 May 07; 12(5). PMID: 32369904    Free PMC article.
Assessment of Long-term Distant Recurrence-Free Survival Associated With Tamoxifen Therapy in Postmenopausal Patients With Luminal A or Luminal B Breast Cancer.
Nancy Y Yu, Adina Iftimi, +10 authors, Linda S Lindström.
JAMA Oncol, 2019 Aug 09;. PMID: 31393518    Free PMC article.
Profiling of Invasive Breast Carcinoma Circulating Tumour Cells-Are We Ready for the 'Liquid' Revolution?
Marcin Braun, Aleksandra Markiewicz, +2 authors, Hanna Romańska.
Cancers (Basel), 2019 Jan 30; 11(2). PMID: 30691008    Free PMC article.
Review.
Gene Expression Assays for Early-Stage Hormone Receptor-Positive Breast Cancer: Understanding the Differences.
Ana Tablante Nunes, Deborah E Collyar, Lyndsay N Harris.
JNCI Cancer Spectr, 2017 Dec 11; 1(1). PMID: 31360834    Free PMC article.
Review.
Genomic Signatures in Luminal Breast Cancer.
Julian Puppe, Tabea Seifert, +3 authors, Wolfram Malter.
Breast Care (Basel), 2020 Sep 29; 15(4). PMID: 32982645    Free PMC article.
Review.
Beyond Chemotherapies: Recent Strategies in Breast Cancer Treatment.
Arthur Foulon, Pierrick Theret, Lise Rodat-Despoix, Philippe Kischel.
Cancers (Basel), 2020 Sep 20; 12(9). PMID: 32947780    Free PMC article.
Review.
Comparison of breast cancer prognostic tests CanAssist Breast and Oncotype DX.
Aditya K Sengupta, Aparna Gunda, +4 authors, Manjiri M Bakre.
Cancer Med, 2020 Oct 08; 9(21). PMID: 33027559    Free PMC article.
PTPN2 deficiency along with activation of nuclear Akt predict endocrine resistance in breast cancer.
Elin Karlsson, Cynthia Veenstra, +3 authors, Olle Stål.
J Cancer Res Clin Oncol, 2018 Dec 06; 145(3). PMID: 30515568    Free PMC article.
Multiple roles of HOX proteins in Metastasis: Let me count the ways.
Joy Jonkers, Priya Pai, Saraswati Sukumar.
Cancer Metastasis Rev, 2020 Jun 24; 39(3). PMID: 32572656
Review.
Magee Equations™ and response to neoadjuvant chemotherapy in ER+/HER2-negative breast cancer: a multi-institutional study.
Rohit Bhargava, Nicole N Esposito, +11 authors, David J Dabbs.
Mod Pathol, 2020 Jul 15; 34(1). PMID: 32661297
Recent Discoveries of Macromolecule- and Cell-Based Biomarkers and Therapeutic Implications in Breast Cancer.
Hsing-Ju Wu, Pei-Yi Chu.
Int J Mol Sci, 2021 Jan 14; 22(2). PMID: 33435254    Free PMC article.
Review.
Genomic Assays in Node Positive Breast Cancer Patients: A Review.
Maroun Bou Zerdan, Maryam Ibrahim, +2 authors, Hazem I Assi.
Front Oncol, 2021 Mar 06; 10. PMID: 33665165    Free PMC article.
Review.